The Role of Amyloid in Type 2 Diabetes

News
Article

How does amyloid in the pancreatic islets contribute tothe development and progression of type 2 diabetes?

How does amyloid in the pancreatic islets contribute tothe development and progression of type 2 diabetes?Also, does amyloid have a direct effect on beta cells?
-- Peter Hayden, MD
    Camdenton, MoThe deposition of amyloid in beta cells has the sameeffect as in other tissues. It disrupts the normalmolecular relationships in these cells, which resultsin abnormal functioning. In addition, it causesthe cells to age more quickly and to die earlier.This leads to a diminished capacity for secreting insulin.
-- Gerald Bernstein, MD
    Associate Clinical Professor of Medicine
    Albert Einstein College of Medicine
    New York

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces / image credit courtesy of Mayo Clinic

CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces

Grace Halsey
January 16th 2025
Article

"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Atumelnant Demonstrates Rapid and Sustained Biomarker Reduction in Phase 2 Trial in Adults with Congenital Adrenal Hyperplasia / image credit ©Sebastian Kaulitzki/stock.adobe.com

Atumelnant Demonstrates Rapid and Sustained Biomarker Reduction in Phase 2 Trial in Adults with Congenital Adrenal Hyperplasia

Grace Halsey
January 10th 2025
Article

Atumelnant treatment resulted in statistically significant reductions in serum androstenedione and 17-OHP as well as notable improvements in CAH symptoms.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

Grace Halsey
January 8th 2025
Article

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

Lexicon Receives Complete Response Letter for Sotagliflozin in Type 1 Diabetes and Chronic Kidney Disease

Lexicon Receives Complete Response Letter for Sotagliflozin in Type 1 Diabetes and Chronic Kidney Disease

Denise Myshko
January 3rd 2025
Article

In November 2024, an FDA advisory committee said the benefits of sotagliflozin do not outweigh the risks in adults with type 1 diabetes and chronic kidney disease.

© 2025 MJH Life Sciences

All rights reserved.